Related Experiment Video
Updated: Dec 3, 2025
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Effect of blood analysis and immune function on the prognosis of patients with COVID-19
Yue-Qiang Fu1,2,3,4, Yue-Lin Sun1,3,4, Si-Wei Lu1,3,4
1Department of Critical Care Medicine, Children's Hospital, Chongqing Medical University, Chongqing, P.R. China.
Insights
Decreased lymphocyte, CD3+, and CD4+ counts indicate poor outcomes in COVID-19 patients. High admission neutrophil counts are linked to mortality, highlighting key blood parameters for monitoring.
Area of Science:
- Immunology
- Hematology
- Infectious Diseases
Background:
- Coronavirus Disease 2019 (COVID-19) poses significant global health challenges.
- Understanding prognostic markers is crucial for managing severe cases.
- Changes in immune cell counts and blood parameters are observed in COVID-19.
Purpose of the Study:
- To investigate the relationship between blood parameters, cellular immune function, and mortality in hospitalized COVID-19 patients.
- To identify predictive markers for in-hospital death.
Main Methods:
- Retrospective study of 85 COVID-19 patients admitted between February 4-16, 2020.
- Analysis of baseline blood parameters and cellular immune markers.
- Primary outcome: in-hospital death.
Main Results:
- Non-survivors had higher baseline leukocyte, neutrophil counts, and hemoglobin compared to survivors.
- Survivors had higher lymphocyte, platelet, PaO2/FiO2, CD3+, and CD4+ counts.
- Neutrophil count > 6.3×10^9/L independently predicted mortality.
- Leukocyte, neutrophil, lymphocyte, CD3+, and CD4+ counts at baseline predicted mortality.
Conclusions:
- Decreased lymphocyte, CD3+, and CD4+ counts are associated with poor outcomes in COVID-19.
- Admission neutrophil count > 6.3 ×10^9/L is an independent predictor of mortality.
- Baseline leukocyte, neutrophil, lymphocyte, CD3+, and CD4+ counts require attention for predicting COVID-19 mortality.
Introduction:
This retrospective study investigated the implications of changes in blood parameters and cellular immune function in patients with Coronavirus Disease 2019 (COVID-19).
Methods:
Records were reviewed of 85 patients admitted with COVID-19 between February 4 and 16, 2020. The primary outcome was in-hospital death.
Results:
Fourteen patients died. The baseline leukocyte count, neutrophil count and hemoglobin was significantly higher in non-survivors compared with survivors, while the reverse was true of lymphocyte count, platelet, PaO2/FiO2, CD3+ count and CD4+ count. The percentage of neutrophil count > 6.3×109/L in death group was significantly higher than that in survival group, and multivariate logistic regression showed neutrophil count > 6.3×109/L was independently associated with mortality. However, there were not significant difference in IgG, IgM, IgA, C3, C4 and the percentage of IgE > 100 IU/ml between the death group and survival group. Areas under the receiver operating characteristic curves of the following at baseline could significantly predict mortality: leukocyte, neutrophil, lymphocyte, CD3+ and CD4+ counts.
Conclusions:
For hospitalized patients with COVID-19, lymphocyte, CD3+ and CD4+ counts that marked decrease suggest a poor outcome. Admission neutrophil count > 6.3 ×109/L is independently associated with mortality. At admission, leukocyte, neutrophil, lymphocyte, CD3+ and CD4+ counts should receive added attention.
